ECTRIMS

Satralizumab Benefits Relapse Risk Across NMOSD Treatment Spectrum

September 29, 2020

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

Ponesimod Shows Safe Cardiac Profile in MS

September 28, 2020

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.

Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibition in Progressive MS

September 26, 2020

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Low-Dose Rituximab Safe, as Effective as High Dose in MS

September 24, 2020

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.

Ocrelizumab Shows Range of Benefits for Spectrum of Patients With Multiple Sclerosis

September 24, 2020

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach

September 23, 2020

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.